LpxC from P.aeruginosa with the inhibitor 6-(benzimidazol-1-yl)-5-[4-[2-[6-[(4-methylpiperazin-1-yl)methyl]-3-pyridyl]ethynyl]phenyl]pyridine-3-carbohydroxamic acid

Overexpression of Pseudomonas aeruginosa LpxC in the Presence of an Inhibitor in an acrB Deletion Escherichia coli strain for Structural Studies

Rigaku VariMax; graded, multilayer confocal optic

UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase

Protein EnvA, UDP-3-O-acyl-GlcNAc deacetylase

Cocrystallization; protein in the following buffer: 20mM HEPES pH7.3, 150 mM NaCl, 2mM DTT, 10% Glycerol and concentrated to 11.3 mg/ml. Well solution contained: 2.2M ammonium sulfate, 0.1 M Tris pH 8.3, 4.1% PEG 400, 29 mM NaPO4 di-basic. Protein coexpressed with compound and well solution were combined 1:1 as a sitting drop. Crystals harvested approximately 21 days later., VAPOR DIFFUSION, SITTING DROP, temperature 293K

UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (E.C.3.5.1.-)

hydroxamate, beta-alpha-alpha-beta sandwich, deacetylase, intracellular; cytoplasm, HYDROLASE-HYDROLASE INHIBITOR complex